Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Xcyte T-cell product enters phase I/II trial in multiple myeloma

May 12, 2003

Initiation of phase I clinical trial of TTS-CD3 in patients with NSCLC

May 12, 2003

Phase I trial of HER-2 Protein AutoVac cleared to begin

May 7, 2003

Enrollment completed in phase IIa Onyvax-P trial

May 5, 2003

Potentially more effective BCG-based therapy for bladder cancer discussed at AUA meeting

April 30, 2003

Antitumor efficacy reported for a novel monoclonal antibody in advanced renal cell carcinoma

April 29, 2003

FavId phase II study expanded

April 28, 2003

TTS-CD2 prolongs survival in NSCLC

April 28, 2003

Virulizin phase III trial extended to Canada and Mexico

April 23, 2003

Revimid granted fast track status for myelodysplastic syndromes

April 17, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...